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age-related macular degeneration 
Cette étude clinique investigue les caractéristiques des yeux perdant secondairement d'acuité visuelle malgré le traitement 
de la dégénérescence maculaire liée à l'âge par Ranibizumab selon besoin qui en moyenne stabilise la vision. La 
dégénérescence maculaire liée à l'âge (DMLA) est une des causes, avec la rétinopathie diabétique, le glaucome et la 
cataracte, parmi le plus importantes, de malvoyance dans les pays industrialises . Il s'agit d'une altération dégénérative 
maculaire qui se traduit par une baisse progressive de la vision et qui évolue vers une perte de la vision centrale. La 
DMLA peut se présenter sous deux formes, soit la forme atrophique, sèche ou la forme exsudative, humide. La forme 
atrophique correspond à une atrophie de la macula, la forme exsudative se caractérise par la croissance de nouveaux 
vaisseaux choroïdiennes (NVC) et se subdivise en trois formes: DMLA à prédominance classique, DMLA exclusivement 
occulte et DMLA classique minimale. Le traitement par inhibition du facteur de croissance de l'endothélium vasculaire 
(VEGF) a été prouvé sécuritaire et efficace pour ce qui concerne la dégénérescence maculaire liée à l'âge (DMLA). Le 
Ranibizumab consiste en une fraction d'un anticorps monoclonal recombinant qui neutralise l'activité biologique de 
toutes les formes actives de VEGF. Dans la pratique clinique la plupart des spécialistes de la rétine emploient des 
inhibiteurs du VEGF selon besoin sur la base des résultats de l'étude PrONTO. Cette étude consiste en un protocole que, 
après trois injections initiales de Ranibizumab données une fois par mois, prévoit des visites mensuelles au bout de 
déterminer une éventuelle nécessité de retraitement. Cette étude est consacrée à l'investigation des caractéristiques des 
yeux qui ayant été traités par Ranibizumab selon besoin, selon les principes décrites dans l'étude PrONTO, ont 
secondairement présenté une baisse de l'acuité visuelle de plus de 5 lettres (EDTRS). L'hypothèse est que la présence de 
liquide récurrent, du à l'incomplète suppression du VEGF et mesurée comme variation d' épaisseur rétinien à la 
tomographie de cohérence optique, puisse traduire cette perte d'acuité visuelle dans la phase de retraitement. Cette 
hypothèse se base sur le fait que la DMLA exsudative non traitée, ou insuffisamment traitée, est associée à une baisse 
progressive de l'acuité visuelle. Dans ce travail on prend en considération une série consécutive des patients avec DMLA 
qui, après avoir reçu 3 injections intravitréenne (0,5 mg) de Ranibizumab mensuelle, ont été retraités à cause de la 
présence de liquide objectivé par tomographie en cohérence optique, depuis mars 2006 et octobre 2009 dans un centre 
unique (Hôpital ophtalmique universitaire Jules-Gonin, Lausanne, Suisse). Les critères d'inclusion dans cette analyse 
nécessitant que les yeux avec DMLA n'avaient pas été traités préalablement et que la durée du suivi étant au moins de 12 
mois depuis le début du traitement par Ranibizumab avec des visites mensuelles, les critères d'exclusion étant des 
traitement oculaires préalables et une interruption des visites régulières mensuelles avant 12 mois .Un total de 99 patients 
étant inclus dans cet étude. Les visites mensuelles comprenaient une anamnèse médicale et oculaire détaillée, une 
évaluation de l'acuité visuelle, un examen biomicroscopique à la lampe à fente et du fond d'œil et un OCT; une 
angiographie à la fluorescéine (AF) étant performée au début, par la suite à discrétion de l'examinateur ou, de façon 
systématique, pour les cas avec baisse de AV ne pouvant pas être expliquée par l'OCT, si évidence d'hémorragie 
maculaire ou si intervalle d'au moins 6 mois depuis la dernière angiographie de contrôle. Après les 3 injections de charge 
le traitement était interrompu pour les yeux qui montraient absence d'écoulements à partir des NCV à l'AF et absence de 
liquide sous-rétinien ou intrarétinien à l'OCT. 
Au contraire, les yeux montrent la présence de liquide au niveau de la macula à l'OCT et/ou une augmentation de 
l'épaisseur centrale rétinien (CRT) de au moins 50 ~Lm ou l'apparition d'une nouvelle hémorragie, recevaient une nouvelle 
injection de Ranibizumab. En fonction du type d'évolution de l'acuité visuelle pendant la période de retraitement sur 
besoin, les patients étant répartis en deux sous-groupes: Je Groupe A, constitué par ceux ayant maintenu ou amélioré le 
niveau de BCVA (best-corrected AV), ou ayant perdu au maximum moins de 4 lettres d'acuité visuelle sur l'échelle 
ETDRS à partir du 3ème mois jusqu'à la date de la dernière visite, le Groupe B, constitué par ceux ayant perdu au moins 
5 lettres d'acuité visuelle sur l'échelle ETDRS au douzième mois. L'analyse des caractéristiques oculaires au début du 
traitement (CNV à prédominance classique, CNV occulte, CNV classique minimale, décollement de l'épithélium 
pigmentaire, atrophie, fibrose, hémorragie) et des facteurs associés (nombres d'injections, variation d'épaisseur rétinienne 
a mis en évidence: 
- association entre présence de PED initiale avec une baisse de l'A V secondaire. 
- absence d'association entre baisse de l'AV secondaire avec les fluctuations individuelles de CRT ou avec le nombre 
d'injections requises. 
- absence d'association entre baisse de l'AV secondaire et changement de l'AV initiale, type angiographie de CNV et 
présence ou absence de fibrose, atrophie, hémorragie ou décollement de l'épithelium pigmentaire. 
Sur la base d'un analyse clinique des dossiers avec perte secondaire de l'A V, on estime que les lésions tissulaires 
secondaires aux déchirures de l'épithélium pigmentaire, atrophie ou fibrose rétinienne progressive et ou à la présence 
d'hémorragies massives, soient des éléments relevantes de pouvoir causer une baisse secondaire de l'AV malgré la 
suppression du VEGF et que la présence au début du traitement de PED peuvent être un facteur de risque importante. 
Il serait justifié de mener des études complémentaires pour identifier l'impact des fluctuations de l'épaisseur rétinien 
centrale pendant un traitement sur besoin par Ranibizumab dans la cadre du traitement de la DMLA. 
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Abstract 
Purpose The aim of this work is to investigate the 
characteristics of eyes failing to maintain visual acuity 
(VA) receiving variable dosing ranibizumab for neovascular 
age-related macular degeneration (nAMD) after three initial 
loading doses. 
Methods A consecutive series of patients with nAMD, 
who, after three loading doses of intravitreal ranibizumab 
(0.5 mg each), were re-treated for fluid seen on optical 
coherence tomography. After exclusion of eyes with 
previous treatment, follow-up less than 12 months, or 
missed visits, 99 patients were included in the analysis. The 
influence of baseline characteristics, initial VA response, 
and central retinal thickness (CRT) fluctuations on the VA 
stability from month 3 to month 24 were analyzed using 
subgroups and multiple regression analyses. 
Results Mean follow-up duration was 21.3 months (range 
12--40 months, 32 patients followed-up for 2':24 months). 
Secondary loss of VA (loss of five letters or more) after 
month 3 was seen in 30 patients (mean VA improvement 
from baseline +5.8 letters at month 3, mean loss from 
baseline -5.3 letters at month 12 and -9.7 at final visit 
up to month 24), while 69 patients maintained vision 
(mean gain +8.9 letters at month 3, +10.4 letters at 
month 12, and + 12.8 letters at final visit up to month 24). 
Secondary loss of VA was associated with the presence of 
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pigment epithelial detachment (PED) at baseline (p 0.01 ), 
but not with baseline fibrosis/atrophy/hemorrhage, CRT 
fluctuations, or initial VA response. Chart analysis 
revealed additional individual explanations for the sec-
ondary loss of VA, including retinal pigment epithelial 
tears, progressive fibrosis, and atrophy. 
Conclusions Tissue damage due to degeneration of PED, 
retinal pigment epithelial tears, progressive fibrosis, pro-
gressive atrophy, or massive hemorrhage, appears to be 
relevant in causing secondary loss of VA despite vascular 
endothelial growth factor suppression. PED at baseline may 
represent a risk factor. 
Keywords Age-related macular degeneration · 
Anti-VEGF · Ranibizumab · Visual acuity loss · 
Pigment epithelial detachment 
Introduction 
The inhibition of vascular endothelial growth factor A 
(VEGF-A) has proven to be an effective and safe therapy 
of neovascular age-related macular degeneration (nAMD) 
[1-3]. Ranibizumab, a recombinant, humanized, monoclo-
nal antibody fragment, inhibits all biologically active 
fom1s of VEGF. Intravitreal injections of this molecule 
have been investigated in large phase III clinical studies, 
which resulted in level I evidence of effectiveness and 
safety of this drug. Monthly injections over the course of 
2 years were administered to predominantly classic [l, 2], 
minimally classic, and occult choroidal neovascularization 
(CNV) [3], and, on average, visual acuity (VA) improved 
by approximately 1-2 lines, which was highly significant. 
This mean gain in VA was maintained for over 2 years with 
monthly injections. 
igi Springer 
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In the PIER study of three consecutive monthly 
injections followed by fixed quarterly injections [ 4, 5], 
ranibizumab brought about an initial improvement in mean 
VA, followed by a decline ofmean VA thereafter, suggesting 
that quarterly treatment is inferior to monthly treatment. 
However, a subgroup of patients did well and maintained 
their initial VA gain [5, 6]. The EXCITE study directly 
compared the results of the PIER quarterly regimen with 
those of monthly injections [7]. In that study, VA gain 
decreased slightly with quarterly dosing, but increased 
slightly with monthly doses of ranibizumab. 
In clinical practice, most retina specialists employ a 
variable dosing regimen based on the results of the 
PrONTO study [8]. In the PrONTO study, after an initial 
loading dose of three injections of ranibizumab given once 
a month, the patients underwent monthly follow-up visits to 
detem1ine their need for re-treatment. The most common 
reasons for re-treatment were changes seen on optical 
coherence tomography (OCT) (recurrent or persistent fluid 
or increased central retinal thickness [CRT] of > 1 OO µm) 
[8]. Although a small and non-comparative study, results of 
the PrONTO study were highly suggestive that mean VA 
results comparable to those of the MARINA/ANCHOR 
study could be achieved with a variable dosing regimen. 
However, the initial VA gain was not entirely maintained. 
A meta-analysis has shown that all variable dosing 
regimens tend to result in a partial loss of the initial effect, 
while fixed monthly dosing results in a slight increase in VA 
after month 3 [ 6]. 
The aim of the present study was to investigate the 
particular characteristics of those eyes with secondary loss 
of VA that were treated in a routine clinical practice with a 
variable dosing regimen of ranibizumab according to the 
principles of the PrONTO study. 
Materials and methods 
We report an observational study of a consecutive series 
of patients with nAMD, who, after the initial 3-monthly 
loading doses of intravitreal ranibizumab (0.5 mg each), 
were re-treated for fluid seen on optical coherence 
tomography at a single center (University Eye Hospital 
Jules Gonin, Lausanne, Switzerland) between March 
2006 and October 2009. To be included in the analysis, 
the eye with nAMD had to be treatment-naive before 
initiation of the ranibizumab treatment, and follow-up 
duration had to be a minimum of 12 months from 
initiation of ranibizumab treatment, with monthly visits. 
A total of 99 patients met the criteria and were included 
in the study, which was performed in accordance with the 
tenets of the Declaration of Helsinki for research 
involving human subjects. 
~ Springer 
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Bach patient underwent a baseline assessment of best-
corrected VA (BCVA) measured at 4 m with standard 
ETDRS charts, and had an ophthalmic examination that 
included slit-lamp biomicroscopy, fluorescein angiography 
(FA), indocyanine angiography (ICG), and OCT (Stratus 
OCT3, Carl Zeiss Meditec, Inc., Oberkochen, Germany) 
utilizing six diagonal, slow 6-mm-radial line scans (soft-
ware version 4.0). The central 1-mm subfield with averaged 
retinal thickness was used as the CRT. In cases of poor 
positioning of the fovea and/or false positioning of the 
automatically set marker lines, the investigator chose one 
line (with the fovea) and averaged the manual measurement 
of the fovea and 0.5 mm from the fovea on both sicles. 
Initial treatment consisted of three intravitreal injections 
of ranibizumab (each injection being 0.5 mg) at monthly 
intervals; all injections were performed by a retina 
specialist according to the usual technique. 
After the three loading doses, each patient underwent a 
monthly visit with detailed medical and ocular history, as 
well as assessment of BCVA, slit-lamp biomicroscopy, 
fundus biomicroscopy, and OCT; FA was perfom1ed at the 
discretion of the examiner. As a rule, FA was performed in 
those cases in which loss of VA could not be explained by 
OCT, if there was a large macular hemorrhage, or if 
6 months had passed since the last FA. 
Intravitreal ranibizumab injection was discontinued after 
month 3 (maintenance phase) in eyes that showed an 
absence of leakage from the CNV on FA, and a dry macula 
(absence of subretinal fluid and cystic maculopathy) on 
OCT. Eyes that showed persistent leakage from the CNV on 
FA and/or fluid in the macula on OCT and/or increased CRT 
of more than 50 µm (compared with smallest previous 
measurement) and/or new hemorrhage received an addi-
tional injection. Pigment epithelial detachment (PED) was 
not a reason for re-treatment if the overlying retina was dry. 
Data collected at each visit included date of the visit, 
visual acuity (letters correctly identified on an ETDRS 
chart), CRT (OCT Stratus), and treatment decision (ranibi-
zumab injection or no injection). Missing data from 
intermediate visits were completed by canying forward 
infommtion from the last observation. Baseline character-
istics included age, gender, eye, angiographie type of CNV 
(predominantly classic, minimally classic, occult, or retinal 
angiomatous proliferation, as determined by a retina 
specialist), lesion size (dise diameters), presence or absence 
of PED, and presence or absence of foveal fibrosis/atrophy/ 
hemorrhage, or hemorrhage covering more than 50% of the 
total lesion size. 
For data analysis, the statistical program JMP, version 
8 (SAS institute Inc., Cary NC, USA), was used. Visual 
acuity changes were calculated by letters identified on the 
ETDRS chart. Time intervals were calculated in days 
(30 days= 1 month). At the start of the study, a description 
Graefes Arch Clin Exp Ophthalmol (2011) 249:1635-1642 
of the patients was obtained, including the number of 
injections, mean VA, and mean CRT findings. As a second 
step, the patients were classified into one of two subgroups 
depending on their VA curves during the variable dosing 
phase (after month 3): Group A consisted of the "main-
tainers", defined as those patients who had the same or 
better BCVA or who had experienced a maximum loss of 
four letters (less than one line loss on the ETDRS chart) 
from month 3 until the latest visit between months 12 and 
24. Group B consisted of the "lasers", those patients who 
experienced a loss of BCVA of five or more letters from 
month 3 to the most recent observation. The Wilcoxon/ 
Kruskal-Wallis test was used to investigate any potential 
association with the following parameters: initial VA 
response after the 3-monthly loading doses; difference 
between the CRT measurements and the thinnest ever 
measured CRT value of the same patient, averaged over the 
follow-up period (=mean CRT excess ); number of injections 
per year of follow-up. Fisher's exact test was used for 
analyzing potential associations with categorical data 
(presence of PED; presence of fibrosis/atrophy/hemorrhage 
at baseline). 
1637 
Because of the somewhat arbitrary threshold between the 
two groups, the results were verified by a second approach 
using multiple linear regression analysis. 
Results 
The 99 patients included in this study consisted of 32 men 
and 67 women; the mean age of the patients was 78 years 
(SD [standard deviation] 8.8 years). Based on baseline FA 
and ICG, 22 patients presented with predominantly classic 
CNV, five had minimally classic CNV, 58 had occult CNV, 
and 14 had retinal angiomatous proliferation. The mean 
follow-up for al! patients was 21.3 months, which ranged 
from 12 to 40 months. Thirty-two patients completed 
24 months of follow-up. 
Baseline VA ranged from 0.05 (20 letters) to 0.8 (80 letters). 
Mean VA on ETDRS (Fig. la) was 59.2 letters at baseline, but 
this rose to 66.6 letters (+7.4 letters) after the first three 
injections, then began to drop slightly after month 11 to a 
level of 64.8 (+5.6 letters) and to 62.6 (+3.4 letters) at 
months 12 and 24, respectively (number ofpatients=99 and 
70.0 ·-·----·-------"'""'"--0-·----·--""---··· .. -----·--·------·----·---.. -----, -----~ ?tt~~1,iH~~ 613.0 :Q œ.o Fl 64.0 
"' ~ 62.0 ····~n--~fnc!usion crihnia.cf 
Marinn, 
- W.0+-1'-<-r-------------------~...._.,H 
.. ,..;:,....... n"61 n=53 n=41 n=27 n=:ni :~1~! 
58.0 1 .,.....,.~~---' 
'li' 
œ.o+-~~~~~-..-..........--,...-...,._..,.......,.......,..-...-..---,..-,,.....,--,_,......,._,,._, 
o 1 2 3 4 5 s 1 a s 10 11 12 13 u 1s m 11 18 1s 20 21 22 23 24 
month 
~ ~01 .. --.~,~-----------.. ·----·---------·--·-.. ----··----·-.. -------------~ g 
Î260t---tt-r-+c--K-+-t--t-1--t--t-t-t--:---r-r--r----:::---rl 
li: li 240 ' 
Ë 
220 
200 ~~~~-~~-.--< 
O t 2 3 4 5 6 7 8 9 10 11 12 13 14. Hl 16 17 1B 19 20 21 22 23 24 
month 
,_,.ô., ,,fnclusiGn 
cf'ileria cf 
tvfarîna, 
Anchor 
s1udîll$ 
Fig. 1 Mean visual acuity curve and mean central retinal thickness 
curve of patients with age-related macular degeneration treated with 
intravitreal ranibizumab. a Mean visual acuity curve (ETDRS letter 
score) for ail included patients treated with variable dosage intravitreal 
ranibizumab for exudative age-related macular degeneration. Error 
bars indicate ± 1 standard error of the mean visual acuity change from 
baseline. Mean follow-up was 21.3 months (range 12-40 months). 
The number of patients who completed 12, 15, 18, 21, and 24 months, 
respectively, are indicated (n). The second curve (without error bars) 
represents the 61 patients with baseline criteria corresponding to 
inclusion criteria of the MARINA and ANCHOR studies. b Mean 
central retinal thickness (CRT) curve in micrometers of mean values 
for the central subfield on optical coherence tomography measurement 
for ail includ~d patients treated with variable dosage intravitreal 
ranibizumab for exudative age-related macular degeneration. Error 
bars indicate ± 1 standard error of the mean central retinal thickness 
change from baseline. The second curve (without error bars) are the 
61 patients with baseline criteria corresponding to inclusion criteria of 
the MARINA and ANCHOR studies 
~ Springer 
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32, respectively). Visual acuity improved by 15 letters or 
more in 24 and 25% of the affected eyes by month 12 and 
month 24, respectively. It improved by 0 letters or more in 
80% and 70% of the eyes by month 12 and month 24, 
respectively. No more than 15 letters were lost in 94 and 89% 
of the eyes by month 12 and month 24, respectively. 
Visual acuity response (letter change from baseline) at 
month 3 was moderately well correlated with the outcome at 
12 months (Pearson correlation coefficient r=0.51, p<0.01), 
and with the final outcome at up to month 24 (r=0.52, 
p<0.01, Fig. 2). The level of baseline VA showed an 
insignificant inverse correlation (r=-0.26), and no cor-
relation was found with age (r=-0.12) or with baseline 
lesion size (r=-0.09). 
The mean number of injections was 6.6 per year of 
follow-up (range, 3-12; SD 1.5). 
Mean CRTwas 306 µmat baseline, but this decreased to 
24 7 µm at mon th 3 and was maintained thereafter (Fig. lb). 
Individual CRT fluctuations from month 3 to month 24, 
however, resulted in individual differences between the 
minimal and the maximal value, which ranged between 
5 and 238 µm (mean, 58 µm; SD, 39 ~Lm). 
Exclusion of the 38 patients whose baseline measure-
ments were outside the criteria of the MARINA and 
ANCHOR studies did not significantly change the visual 
acuity outcome or mean CRT outcome at any time point 
(Fig. la and b). 
Separating the patients into subgroups A and B, 
differentiating between those who "maintained" VA after 
month 3 and those who "lost" VA after month 3 (described 
in the "Materials and methods" section), revealed that 69 
~ 
80 
60 
40 
~ 20 
~ 0 ~ 
-20 
-40 
-40 -30 -20 -10 0 10 20 30 40 50 60 70 
ETDRS M3-MO 
Fig. 2 Correlation between visual acuity change after initial three 
injections of ranibizumab and final visual acuity change. Bivariate fit 
of ETDRS letter score change at last visit, up to month 24, by letter 
score change at month 3 (as compared to baseline letter score). 
Mathematical equation: (ETDRS M24-M0)=-3.29+ l.12*(ETDRS 
M3-MO). Pearson correlation coefficient r=0.52, p<0.01 
%) Springer 
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were maintainers and that 30 were losers. Mean follow-up 
duration was 21.2 months in the maintainer group, and 
22.0 months in the loser group. Mean baseline BCVA was 
61 letters (SD 16) in the loser group, and 58 letters (SD 15) 
in the maintainer group, which did not represent a 
significant difference. The mean BCVA curves of these 
two groups did diverge after month 3 but little change was 
found after month 12, as shown in Fig. 3a. Most lasers 
were assigned to their category by month 12 (25 out of30). 
The remaining five eyes changed their category after month 
12 with mild VA loss only, while eight other eyes were 
transiently in the laser category by month 12, recovering 
thereafter. Lasers showed a mean VA improvement from 
baseline of +5.8 letters (SD 8.5) at month 3, a mean VA loss 
from baseline of -5.3 letters (SD 10.2) at month 12, and a 
loss of -9.7 (SD 9.9) at the final visit, up to month 24 
(mean secondary visual loss was -16.5 letters, SD 12.5). 
The 69 patients who maintained their vision showed a mean 
gain of +8.9 letters (SD 13.4) at month 3; +10.4 letters (SD 
9.5) at month 12 and a gain of+ 12.8 letters (11.3) at the final 
visit (mean secondary visual change was a gain of +4.4 letters 
(SD 7.2). In terms ofmean CRT, there was a mild statistically 
insignificant, difference, with slightly thicker central retinal 
subfields seen on OCT in the group of visual acuity lasers 
(Fig. 3b). However, this curve did not reflect individual 
variations in retinal thiclmess as this disappeared in the 
averaged values. VA maintainers showed a mean CRT excess 
(after month 3) of 55 µm (SD 32), while VA lasers had a 
mean excess of 61 µm (SD 48) (statistically insignificant, 
Table l ). In ail eyes, the fluid had disappeared complete[y at 
the time of their best anatomie response, except for one 
patient in the !oser group who had persistent subretinal 
fluid despite monthly treatment. The number of inj ec-
tions per year was similar in both groups (secondary 
lasers: mean 7.8 injections, SD 2.0, in year 1 and 6.5 
injections, SD 2.2, in year 2 for those reaching 
24 months; maintainers: mean 7.7 injections, SD 2.1, in 
year 1 and 6.3 injections, SD 2.3, in year 2 for those 
reaching 24 months). Table 1 provides an overview of the 
statistical analyses, which showed no significant differ-
ences in initial VA response, mean CRT excess or number 
of injections during the maintenance phase. 
Baseline characteristics that are known to be associated 
with the overall functional outcome of ranibizumab 
treatment (age, lesion size, VA at baseline, VA change after 
3 months) and did not show any association with the 
subgroup of patients who experienced secondary loss of 
VA. There were significantly more patients with PED in the 
!oser group (ten of 30 patients) than in the maintainer group 
(eight of 69 patients), with a p value of 0.01 (Fisher's exact 
test, Table 1 ). Of the eight cases of PED in the laser group, 
six were found in occult lesions (three fibrovascular, three 
serous ), and two were present in patients with retinal 
Graefes Arch Clin Exp Ophthalmol (2011) 249:1635-1642 1639 
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Fig. 3 Mean visual acuity curves and mean central retinal thickness 
curves in subgroups of secondary visual acuity maintainers and losers. 
a Mean visual acuity curve (ETDRS letter score) of the subgroups: 
Visual acuity maintainers were those patients treated with ranibizumab 
for exudative age-related macular degeneration who maintained best-
corrected visual acuity or lost a maximum of four letters at last 
observation (or until month 24) as compared with month 3. The group 
of secondary visual acuity losers was defined as th ose who lost five or 
more letters after month 3. The number of patients who completed 12, 
15, 18, 21, and 24 months, respectively, are indicated (11). The curves 
angiomatous proliferation (two serous). Seven of the eight 
patients with PED had been assigned to the secondary laser 
category by month 12. However, distribution by angio-
graphie lesion type was similar in bath groups (Chi-square 
test: predominantly classic CNV, p=0.61; minimally classic 
CNY, p=0.28; occult CNV, p=0.16; retinal angiomatous 
proliferation, p=0.12). Furthermore, the presence or absence 
of central atrophy, fibrosis, or hemorrhage at baseline (which 
were inclusion/exclusion criteria of the MARINA and 
ANCHOR studies) did not show any association with the 
subgroups ( eight patients in the maintainer group, five 
patients in the laser group). 
Multiple linear regression analysis was perfonned, with the 
difference between VA at month 3 and at last visit (or until 
mon th 24) as the continuous parameter. Presence of PED at 
baseline was the only factor that remained significant of 
poorer outcome (p = 0.02). 
A systematic review of the medical records of group B 
patients (which consisted of the 30 VA lasers) revealed, 
for each individual, a viable explanation for the decline 
in VA after month 3 (Table 2). Major secondary VA loss 
diverged between months 3 and 12, which corresponded to the early 
phase of the variable dosing regimen after the initial loading doses of 
ranibizumab. b Mean central retinal thickness curves in microns of 
mean values for the central retinal subfield on optical coherence 
tomography of the subgroups as described for Fig. 3a. There was a 
mild statistically insignificant difference with slightly thicker central 
retinal subfields on optical coherence tomography in the group of 
visual acuity losers. This curve does not, however, reflect individual 
variations in retinal thickness as these disappear in averaged values 
occurred in patients with massive hemorrhage during 
follow-up and in those with a retinal pigment epithelial 
(RPE) tear (four patients with PED, two patients without 
PED at baseline), followed by RPE degeneration in 
patients with PED, and foveal atrophy and subfoveal 
fibrosis that developed during follow-up. Minar secondary 
VA loss occurred in cases with strong recurrence of 
exudation, persistent subretinal fluid despite monthly 
treatment, and cataract progression. 
Discussion 
Intravitreal ranibizumab is currently the "gold standard" of 
treatment for nAMD, primarily because of its well-
documented efficacy and safety [l-3]. However, the 
response of VA varies greatly from one individual to 
another. Severa! factors for functional outcome have been 
identified [9-11 ], but the initial functional response after the 
first three injections appears to be particularly predictive of 
the long-term result, bath in our study and in other reports 
<f) Springer 
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Table 1 Statistical analysis of factors potentially involved in 
seconda1y visual acuity loss ( during maintenance phase) in patients 
with exudative age-related macular degeneration treated with variable 
dosage intravitreal ranibizumab 
VA maintainers Secondary VA p 
lasers 
n=69 12=30 
Initial VA change after +8. 9 (SD 13 .4) +5.8 (SD 8.5) 0.58 n.s. 
3-monthly loading 
doses 
Mean CRT excess 55 µm (SD 32) 61 µm (SD 48) 0.76 n.s. 
after month 3 
Number of injections 7 .8. (SD 2.0) 7.7 (SD 2.1) 0.82 n.s. 
during years 1 and 2 
6.5 (SD 2.2) 6.3 (SD 2.3) 0.75 n.s. 
Presence of PED 8 (11.6%) 10 (33.3%) 0.01 
Angiographie lesion pc= 17 (24.6%) pc=6 (20.0%) 0.61 n.s. 
type at baseline 
occ=36 (52.2%) occ=ll (36.7%) 0.16 n.s. 
mc=3 (4.3%) mc=3 (10.0%) 0.28 n.s. 
RAP=13 (18.8%) RAP=lO (33.3%) 0.12 n.s. 
Presence of fibrosis/atrophy/ 8 (11.6%) 
hem01Thage at baseline 
5 (16.7%) 0.19 n.s. 
n.s. not significant; SD standard deviation; VA visual acuity; CRT 
central retinal thickness; PED pigment epithelial detachment; pc 
predominantly classic neovascular membrane; ace occult neovascular 
membrane; me minimally classic neovascular membrane; RAP retinal 
angiomatous proliferation 
in the literature [l I ], possibly indicative of the remaining 
functional potential of the surviving retinal cells. 
The PIER study has shown that Jess than monthly 
treatment (fixed 3-monthly treatments) results in secondary 
loss of the initial VA gain in a subgroup of patients ("gain 
Table 2 Individual clinical causes of secondary visual decline of five 
Ietters or more during maintemmce phase in patients with exudative 
age-related rnacu!ar degeneration treated with variable dosage intra-
vitreal ranibizumab, by degree of secondary visual loss 
Cause 
Massive hemorrhage 
occurring during 
follow-up 
Pigment epithelial tear 
occurring during 
follow-up 
Pigment epithelial detachment 
degeneration 
Fovcal atrophy developing 
during follow-up 
Subfoveal fibrosis developing 
during follow-up 
Persistent subfoveal fluid 
Cataract progression 
Rapid recurrence with 
strong exudation 
Total 
~ Springer 
n Mean visual acuity Mean visual acuity 
2 
6 
7 
7 
30 
change from month 3 change from 
baseline 
-44 -47 
-26 -23 
-18 -9 
-13 -7 
-10 0 
-7 -6 
-5 -5 
-5 0 
-16.5 (SD 12.5) -9,7 (SD 9.9) 
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and not maintain"), in contrast with another subgroup of 
patients, which was termed "gain and maintain" [5, 6]. 
The purpose of the present study was to identify the 
subgroup of eyes responsible for the secondary VA decline 
of the mean VA curve, and to identify associated character-
istics. A small set of baseline characteristics was examined 
(PED, fibrosis, atrophy, hemorrhage), as were some factors 
related to the variable dosing regimen (CRT fluctuations, 
number of injections). 
PED at baseline was associated with statistically 
increased risk of secondmy VA loss after month 3, an 
effect that was independent of the functional response at 
month 3. In the large MARINA and ANCHOR trials, 
although cases of nAMD with PED could potentially be 
included, they were not reported separately. However, a 
recent subgroup analysis of patients with moderate to 
severe visual loss despite monthly anti-VEGF treatment 
found an increased incidence of RPE tears in those with 
poor outcome as compared with those with no visual Joss 
or only mild visual Joss, while no difference was found 
in the baseline area of serous PED [12]. A retrospective 
study of patients with different subfoveal CNV types, 
including a group with PED, did not find any difference in 
short-term VA results (7 months) [13]. However, many 
reports have been published about the risk of RPE tears, 
which are present in about 13-17% of nAMD cases with 
PED [14-17], but which are seen also in the absence of 
PED [ 18, 19]. Height and extension of the PED have also 
been reported to be major risk factors [14, 15]. A tear of 
the RPE can cause significant loss of VA despite VEGF 
suppression, if the fovea is involved [ 16]. Our finding that 
PED may be associated with secondary visual loss after 
month 3 included some cases of RPE tears as well as 
progressive RPE degeneration (Table 2). 
An association with follow-up parameters such as CRT 
fluctuations or number of injections per year could be 
expected, because these parameters may reflect insufficient 
treatment in the group of secondary lasers. The EXCITE 
study showed retinal thickness fluctuations that were of 
major importance in the "gain and not maintain" (and "no 
initial gain") subgroup, suggesting a causal association with 
the loss of VA after month 3 (data on file, Novartis Pharma 
AG, Basel, Switzerland; presented at the SOE Congress of 
the European Society ofOphthalmology, Amsterdam, 2009, 
Prünte et al., on behalf of the EXCITE study group). Thus, 
recurrent retinal exudation might be associated with slow 
loss of BCVA. The variable dosing regimen typically 
requires some signs of exudation (fluid on OCT, exudation 
on FA or hemorrhage on fundus examination) to reappear 
before the patient is re-treated. Thus, during each pre-
treatment period, some damage to the retinal cells may 
theoretically occur, which might ultimately translate to 
irreversible functional loss of vision. A meta-analysis has 
Graefes Arch Clin Exp Ophthalmol (2011) 249:1635-1642 
shown that all variable dosing regimens tend to result in a 
partial loss of the initial effect (similar to our finding), while 
fixed monthly dosing results in a slight increase in VA after 
month 3 [6]. More recent studies evaluating the vaiiable 
dosing with ranibizumab have confirmed the same trend: 
fünctional results at 12 or 24 months are always slightly 
lower than at month 3 [20-23] Furthermore, most of these 
variable dosing regimens result in lower VA gain at month 
12 than would be expected from the MARINA and 
ANCHOR studies [21, 24-27]. However, despite the 
overall trend of losing some of the gained visual acuity, 
some reports have shown relatively good outcomes of the 
variable dosing regimen [8, 22, 23]. 
Recently, Gerding et al. reported a retrospective evalu-
ation that showed a correlation between functional loss of 
VA and a preceding increase in CRT. This loss of VA was 
only partially reversible, and led, in some patients, to a 
permanent functional loss [20]. In a similar way, we chose 
to analyze CRT changes. In the present study, we used 
averaged values of the individual changes :from the thinnest 
ever measured CRT, assuming that the smallest value 
represented the best anatomical outcome, and that any 
higher value was due to liquid (CRT excess). We, however, 
did not find an association of secondary visual loss with 
individual CRT fluctuations or with the number of 
injections. There are several possible explanations for this: 
The retinal CRT variations in our sample are relatively 
moderate, as we re-treated at thickness increases of 50 µm 
(compared to 100 µm in the PrONTO study [8]) or even 
before if other signs of fluid were present on OCT. With 
such mild fluid fluctuations, a larger sample size might be 
needed to show an effect on functional outcome. However, 
as a general rule, clinical relevance decreases progressively 
with increasing number of subjects needed in order to show 
a statistically significant difference. In addition, there are 
significant shortcomings of the Stratus OCT in reproducibly 
quantifying retinal thickness, and segmentation errors 
frequently occur [28]. Patients with reduced VA may have 
difficulty with fixation, and central measurement may have 
to be manually adjusted, resulting potentially in suboptimal 
centralization. The goal of the manual correction used in 
our study was to reduce this problem, although it is not 
possible to completely correct this error. Well-designed 
studies with OCT instruments that more precisely perform 
these measurements are needed to better investigate to what 
degree CRT fluctuations might cause secondary VA loss in 
the variable dosing regimen. 
The number of injections was similar in the "loser" and 
the "maintainer" groups. In the literature, a trend of lower 
efficacy of ranibizumab has been reported in the series with 
fewer re-treatments, particularly if less than five injections 
per year were given [26, 29]. It has been calculated that 8.4 
injections, on average, might be needed to stabilize visual 
1641 
acuity after month 3 [20]. Our series did not show less 
effect with fewer treatrnents, which might be a consequence 
of our very early re-treatrnent criteria, which results in a 
relatively high mean number of re-treatments (an average of 
7.8 injections in the first year, and 6.4 injections in the 
second year). 
The case-by-case chart review of all secondary lasers 
revealed additional individual explanations for VA loss. 
Besides the discussed RPE tears and RPE degeneration 
with persistent PED, there were cases of massive subretinal 
hemorrhage that caused secondary loss of VA, and mild 
secondary VA loss was found to be due to foveal atrophy or 
fibrosis that developed during follow-up. Any of these 
events could potentially occur, even under complete VEGF 
suppression, such as with a monthly regimen of ranibizu-
mab [12]. In the MARINA and ANCHOR studies, 
approximately 5-10% of patients had moderate to severe 
visual acuity loss (more than 3 lines from baseline) 
despite continuous blocking of VEGF [1-3], although 
subgroup analysis revealed an association with lesion 
characteristics commonly associated with suppressed CNV, 
such as pigmentary abnormalities and progression of the 
atrophie scar, in the absence of leakage [12]. Thus, we 
agree with the conclusion that photoreceptor and RPE 
damage may be major factors for long- term loss of VA 
despite VEGF suppression, and future improvements in 
VA of patients receiving ranibizumab therapy may require 
preservation of photoreceptor and RPE cells rather than 
targeting the CNV [12]. 
In conclusion, tissue damage due to PED degeneration, 
RPE tears, progressive fibrosis, progressive atrophy, or 
massive hemorrhage, appears to be relevant in causing 
secondary loss of VA despite VEGF suppression, and 
presence or absence of PED at baseline may be an 
important risk factor. A variable dosing regimen with 
ranibizumab allows overall functional results similar to 
those with monthly treatment; at least if the patient is 
monitored with monthly visits and if early re-treatrnent 
criteria are in place. However, further studies are warranted 
to identify the impact of CRT fluctuations during a variable 
dosing regimen with ranibizumab for nAMD. 
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